Harbor Capital Advisors Inc. Purchases Stake in Biohaven Ltd.

Harbor Capital Advisors Inc. recently purchased 24,189 shares of Biohaven Ltd. during the second quarter, according to a Form 13F filing with the Securities and Exchange Commission. The purchase was valued at approximately $579,000. Several other institutional investors and hedge funds have also made changes to their positions in Biohaven. Allspring Global Investments Holdings LLC bought a new position in the company during the first quarter, while US Bancorp DE and Federated Hermes Inc. boosted their holdings. FSC Wealth Advisors LLC and Dark Forest Capital Management LP also increased their positions.

Wall Street analysts have provided positive outlooks for Biohaven, with many rating the stock as a “Buy.” JPMorgan Chase & Co. dropped their price target from $27.00 to $24.00 and set an “overweight” rating on the stock, while BTIG Research raised their target price from $24.00 to $28.00. Currently, Biohaven has a consensus rating of “Buy” and a consensus price target of $25.25.

Biohaven Ltd. has a 12 month low of $5.54 and a 12 month high of $26.64. The company reported a lower than expected quarterly earnings at ($1.32) EPS.

In recent news, director John W. Childs purchased 50,000 shares of Biohaven stock at an average price of $18.44 per share, totaling $922,000. This brings Childs’ ownership to over 1.9 million shares.

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with neurological and neuropsychiatric diseases. Their pipeline includes products for the treatment of epilepsy, neurological diseases, neuropathic pain, and neurodegenerative diseases.

Sources:
– Source 1
– Source 2